A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study

B. Risslegger, T. Zoran, M. Lackner, M. Aigner, F. Sánchez-Reus, A. Rezusta, A. Chowdhary, S. J. Taj-Aldeen, M. C. Arendrup, S. Oliveri, D. P. Kontoyiannis, A. Alastruey-Izquierdo, K. Lagrou, G. Lo Cascio, J. F. Meis, W. Buzina, C. Farina, M. Drogari-Apiranthitou, A. Grancini, A. M. TortoranoB. Willinger, A. Hamprecht, E. Johnson, L. Klingspor, V. Arsic-Arsenijevic, O. A. Cornely, J. Meletiadis, W. Prammer, V. Tullio, J. J. Vehreschild, L. Trovato, R. E. Lewis, E. Segal, P. M. Rath, P. Hamal, M. Rodriguez-Iglesias, E. Roilides, S. Arikan-Akdagli, A. Chakrabarti, A. L. Colombo, M. S. Fernández, M. T. Martin-Gomez, H. Badali, G. Petrikkos, N. Klimko, S. M. Heimann, J. Houbraken, O. Uzun, M. Edlinger, S. de la Fuente, C. Lass-Flörl*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

Objectives A prospective international multicentre surveillance study was conducted to investigate the prevalence and amphotericin B susceptibility of Aspergillus terreus species complex infections. Methods A total of 370 cases from 21 countries were evaluated. Results The overall prevalence of A. terreus species complex among the investigated patients with mould-positive cultures was 5.2% (370/7116). Amphotericin B MICs ranged from 0.125 to 32 mg/L, (median 8 mg/L). Conclusions Aspergillus terreus species complex infections cause a wide spectrum of aspergillosis and the majority of cryptic species display high amphotericin B MICs.

Original languageEnglish
Pages (from-to)776.e1-776.e5
JournalClinical Microbiology and Infection
Volume23
Issue number10
DOIs
StatePublished - Oct 2017

Funding

FundersFunder number
Aranis
Basilea and Merck
ECMM
EFISGD-155110-017-016
F2G
German Federal Ministry of Research and Education
ISHAM
Inositec AG
Melinta Therapeutics
Merck/MSD
Pfizer & T2Candida
Sanofi Pasteur, Scynexis, Seres Therapeutics
Schering Plough
Sharpe & Dohme
United Medical
National Institutes of HealthUM1AI104681
PfizerWI182172
AstraZeneca
Bayer
Merck
Novartis
Roche
Gilead Sciences
Janssen Biotech
Actelion Pharmaceuticals
Duke University
Medpace
Meso Scale Diagnostics
Schering-Plough
Janssen Pharmaceuticals
Cidara Therapeutics
University of Leeds
GlaxoSmithKline Australia
Austrian Science Fund
Astellas Pharma
Basilea Pharmaceutica

    Keywords

    • Amphotericin B
    • Aspergillosis
    • Aspergillus terreus
    • Crytic species
    • In vitrosusceptibility

    Fingerprint

    Dive into the research topics of 'A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study'. Together they form a unique fingerprint.

    Cite this